共 47 条
[31]
Yan H.-P., Carter C.E., Wang E., Et al., Functional studies on the antipathoangiogenic properties of CM101, Angiogenesis, 2, pp. 219-233, (1998)
[32]
Wamil B.D., Thurman G.B., Sundell H.W., Et al., Soluble e-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trial, J Cancer Res Clin Oncol, 123, pp. 173-179, (1997)
[33]
DeVore R.F., Hellerqvist C.G., Wakefield G.B., Et al., Phase I study of the antineovascularization drug CM101, Clinical Can Res, 3, pp. 365-372, (1997)
[34]
Quinn T.E., Thurman G.B., Sundell A.-K., Et al., CM101, a polysaccharide anti-tumor agent, does not inhibit wound healing in murine models, J Can Res Clin Oncol, 121, pp. 253-256, (1995)
[35]
Abramovitch R., Frenkiel D., Meir G., Et al., Mapping neovascularization and anti-neovascularization therapy: Correlation between NMR and light microscopy, Proceedings of the 5th Conference of the International Society of Magnetic Resonance in Medicine (ISMRM), (1997)
[36]
Hellerqvist C.G., Neeman M., Wamil B.D., Abramovitch R., Facilitation of wound healing with CM101/GBS toxin, (1999)
[37]
Vetvicka V., Thornton B.P., Ross G.D., Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells, J Clin Invest, 98, pp. 50-61, (1996)
[38]
Schaffer C.J., Reinisch L., Polis S.L., Et al., Comparisons of wound healing among excisional, laser-created, and standard thermal burns in porcine wounds of equal depth, Wound Repair Regen, 5, pp. 52-61, (1997)
[39]
Nanney L.B., Epidermal and dermal effects of epidermal growth factor during porcine wound repair, J Invest Dermatol, 94, pp. 624-629, (1990)
[40]
Nanney L.B., Paulsen S., Davidson M., Et al., Boosting of EGF receptorsa by gene gun stimulates epidermal growth in vivo, Wound Repair Regen, 8, pp. 117-127, (2000)